Business Description
PegBio is a Chinese biopharmaceutical company founded in 2008 and headquartered in Hangzhou, dedicated to developing treatments for long-term conditions such as type 2 diabetes, obesity, and liver disease. The company has several drug candidates at various stages of development, including therapies that have already completed early-to-mid stage clinical trials, one that holds FDA orphan drug status for a rare insulin disorder, and others still in preclinical testing. PegBio's work centers on a range of hormonal and receptor-based drug mechanisms that aim to address some of the most widespread and growing health challenges in China and beyond.
